Search results
Results from the WOW.Com Content Network
Pravastatin, sold under the brand name Pravachol among others, is a statin medication, used for preventing cardiovascular disease in those at high risk and treating abnormal lipids. [5] It is suggested to be used together with diet changes, exercise, and weight loss. [ 5 ]
Fewer revascularization procedures: In the pravastatin group, the need for coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) was reduced by 37%. Lower incidence of stroke: Pravastatin therapy was associated with a trend towards a reduction in the incidence of stroke but was not considered statistically significant.
No studies have examined the effect of statins on cognition in patients with prior stroke. However, two large studies (HPS and PROSPER) that included people with vascular diseases reported that simvastatin and pravastatin did not impact cognition. [40] Statins have been studied for improving operative outcomes in cardiac and vascular surgery. [41]
Researchers observed 13,460 patients with stroke and divided the cases based on whether they suffered from a severe or non-severe stroke, which they categorized using a six-point scale that ...
The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the ...
According to the National Heart, Lung, and Blood Institute (NIH), a stroke takes place when blood flow to the brain becomes blocked, or there might be sudden bleeding in the brain.
A new study says that type 2 diabetes medications GLP-1 agonists and SGLT2 inhibitors may help lower a stroke survivor’s risk of experiencing a subsequent stroke, heart attack, or death ...
Prasugrel must not be given to patients with a history of ischemic stroke or aged 75 years or older. In patients with non-ST elevation acute coronary syndrome current guidelines also recommend immediate administration of dual antiplatelet therapy upon diagnosis; clopidogrel and ticagrelor are indicated in this setting, with ticagrelor ...